EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Circulating MicroRNAs in Lung Cancer and Pulmonary Tuberculosis: Diagnostic Potential, Shared Signatures, and Challenges in Differential Diagnosis

Nazgul Khamitova, Aliya Nurmukhanbetova iD, Rifat Hamoudi iD, Madina Kamalieva, Nurlan Jainakbayev, Nurlan Baisynov, Kamalidin Sharipov iD

Diagnostics · 02.11.2026 · 16 (21) · 3619

DOI: 10.3390/diagnostics16213619 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 02.11.2026. Verfasst von Nazgul Khamitova und 6 weiteren Autor:innen. Beteiligte Einrichtung: Aitkhozhin Institute of Molecular Biology and Biochemistry, Almaty 050012, Kazakhstan. Die Arbeit nennt 235 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health of the Republic of Kazakhstan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The differential diagnosis of lung cancer and pulmonary tuberculosis (PTB) remains challenging because the diseases share clinical manifestations and radiological features, particularly in regions with a high tuberculosis burden. This narrative review evaluates circulating microRNAs (miRNAs), primarily measured in serum, plasma and extracellular-vesicle-enriched fractions, as potential adjunctive biomarkers for this differential diagnosis. The literature search was updated through 3 October 2026. Evidence was synthesized by comparator group, biological matrix, analytical methodology and validation design, distinguishing direct lung cancer–PTB comparisons from disease–control studies and prognostic or monitoring investigations. Numerous miRNAs have been associated with either disease, but shared candidates and opposite expression directions across separate studies do not establish differential diagnostic accuracy. Findings vary with patient selection, sample processing, detection platforms, normalization and reference standards. Direct blood-based comparisons remain limited and report variable discrimination. A plasma panel comprising miR-342-3p, miR-199a-3p and miR-199b-3p differentiated PTB from lung cancer with areas under the curve of 0.911 in training and 0.886 in internal split-sample validation; validation sensitivity and specificity were 87.9% and 75.9%, respectively. Its case–control design, incomplete microbiological confirmation and absence of concomitant lung cancer–PTB assessment limit clinical interpretation. Additional pleural-fluid findings concern a separate matrix and cannot be extrapolated to blood testing. Prognostic and treatment-associated findings remain exploratory and do not establish treatment-guiding or validated monitoring utility. Circulating miRNAs should therefore be considered potential adjuncts to clinical assessment, imaging, microbiological testing and histopathology. Clinical translation requires standardized assays, independent prospective validation in clinically relevant populations, and demonstration of incremental value and clinical utility within existing diagnostic pathways. Future studies should prespecify intended use, assay procedures and diagnostic thresholds, include patients with coexisting disease, and evaluate whether testing improves clinical decisions without replacing established microbiological or tissue confirmation methods.

Schlagwörter

Stichwörter der Autor:innen

biomarker panelscirculating microRNAsdifferential diagnosislung cancermolecular diagnosticsnon-invasive biomarkerspulmonary tuberculosisqRT-PCRrespiratory diseasestranslational medicine

Autor:innen und Institutionen

  • Aitkhozhin Institute of Molecular Biology and Biochemistry, Almaty 050012, Kazakhstan.
  • Department of Biophysics, Biomedicine and Neuroscience, Faculty of Biology and Biotechnology, Al-Farabi Kazakh National University, Almaty 050040, Kazakhstan.
  • Department of General Immunology, S.D. Asfendiyarov Kazakh National Medical University, Almaty 050060, Kazakhstan.
  • Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates.
  • Center of Excellence for Precision Medicine, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates.
  • Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates.

ORCID-Profile: Aliya Nurmukhanbetova, Rifat Hamoudi, Kamalidin Sharipov

Förderung

  • Ministry of Health of the Republic of Kazakhstan

Zitieren

APA

Khamitova, N., Nurmukhanbetova, A., Hamoudi, R., Kamalieva, M., Jainakbayev, N., Baisynov, N., & Sharipov, K. (2026). Circulating MicroRNAs in Lung Cancer and Pulmonary Tuberculosis: Diagnostic Potential, Shared Signatures, and Challenges in Differential Diagnosis. Diagnostics, 16(21), 3619. https://doi.org/10.3390/diagnostics16213619

Vancouver

Khamitova N, Nurmukhanbetova A, Hamoudi R, Kamalieva M, Jainakbayev N, Baisynov N, et al. Circulating MicroRNAs in Lung Cancer and Pulmonary Tuberculosis: Diagnostic Potential, Shared Signatures, and Challenges in Differential Diagnosis. Diagnostics. 2026;16(21):3619. doi:10.3390/diagnostics16213619

BibTeX
@article{Khamitova2026,
  author = {Khamitova, Nazgul and Nurmukhanbetova, Aliya and Hamoudi, Rifat and Kamalieva, Madina and Jainakbayev, Nurlan and Baisynov, Nurlan and Sharipov, Kamalidin},
  title = {Circulating MicroRNAs in Lung Cancer and Pulmonary Tuberculosis: Diagnostic Potential, Shared Signatures, and Challenges in Differential Diagnosis},
  journal = {Diagnostics},
  year = {2026},
  volume = {16},
  number = {21},
  pages = {3619},
  doi = {10.3390/diagnostics16213619}
}
Kostenlos starten →